{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:24:39Z","timestamp":1770470679396,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89008-x","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:01:08Z","timestamp":1739170868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"2","key":"89008_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder Cancer in 2023: A systematic review of risk factors. Eur. Urol. 84(2), 176\u2013190 (2023).","journal-title":"Eur. Urol."},{"key":"89008_CR2","doi-asserted-by":"crossref","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 68(6), 394\u2013424 (2018).","DOI":"10.3322\/caac.21492"},{"key":"89008_CR3","doi-asserted-by":"crossref","unstructured":"Babjuk, M. et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81(1), 75\u201394 (2022).","DOI":"10.1016\/j.eururo.2021.08.010"},{"issue":"4","key":"89008_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.eururo.2020.04.059","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh, J. Y. et al. An international collaborative consensus statement on en bloc resection of bladder tumorincorporating two systematic reviews, a two-round delphi survey, and a consensus meeting. Eur. Urol. 78(4), 546\u2013569 (2020).","journal-title":"Eur. Urol."},{"issue":"2 Pt 2","key":"89008_CR5","first-page":"E76","volume":"110","author":"M Richterstetter","year":"2012","unstructured":"Richterstetter, M. et al. The value of extended transurethral resection of bladder tumor(TURBT) in the treatment of bladder cancer. BJU Int. 110(2 Pt 2), E76\u2013E79 (2012).","journal-title":"BJU Int."},{"issue":"6","key":"89008_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"M Cumberbatch","year":"2018","unstructured":"Cumberbatch, M. et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: A systematic review\u00a0. Eur. Urol. 73(6), 925\u2013933 (2018).","journal-title":"Eur. Urol."},{"issue":"1","key":"89008_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/0974-7796.163798","volume":"8","author":"K Hashine","year":"2016","unstructured":"Hashine, K. et al. Results of second transurethral resection for high-grade T1 bladder cancer. Urol. Ann.\u00a0 8(1), 10\u201315 (2016).","journal-title":"Urol. Ann.\u00a0"},{"issue":"8","key":"89008_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig, T. W. et al. NCCN guidelines(R) insights: Bladder cancer, version 2.2022. J. Natl. Compr. Cancer Netw. 20(8), 866\u2013878 (2022).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"89008_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline. J. Urol. 196(4), 1021\u20131029 (2016).","journal-title":"J. Urol."},{"issue":"1","key":"89008_CR10","first-page":"44","volume":"9","author":"YH Jin","year":"2022","unstructured":"Jin, Y. H. et al. Treatment and surveillance for non-muscle-invasive bladder cancer: A clinical practice guideline (2021 edition). Mil.\u00a0Med. Res. 9(1), 44 (2022).","journal-title":"Mil.\u00a0Med. Res."},{"issue":"4","key":"89008_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","volume":"25","author":"A Eroglu","year":"2020","unstructured":"Eroglu, A., Ekin, R. G., Koc, G. & Divrik, R. T. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: Results from randomized 10-year extension trial. Int. J. Clin. Oncol. 25(4), 698\u2013704 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"89008_CR12","doi-asserted-by":"crossref","unstructured":"Gordon, P. C., Thomas, F., Noon, A. P., Rosario, D. J. & Catto, J. Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: A potential to rationalize use\u00a0. Eur. Urol. Focus 5(4), 650\u2013657 (2019).","DOI":"10.1016\/j.euf.2017.10.004"},{"issue":"1","key":"89008_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4111\/icu.20210314","volume":"63","author":"K Lee","year":"2022","unstructured":"Lee, K., Jeong, S. H., Yoo, S. H. & Ku, J. H. Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors. Investig. Clin. Urol. 63(1), 14\u201320 (2022).","journal-title":"Investig. Clin. Urol."},{"issue":"2","key":"89008_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","volume":"73","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter, J. et al. Value of an immediate intravesical instillation of Mitomycin C in patients with non-muscle-invasive bladder cancer: A prospective multicentre randomised study in 2243 patients. Eur. Urol. 73(2), 226\u2013232 (2018).","journal-title":"Eur. Urol."},{"key":"89008_CR15","doi-asserted-by":"crossref","unstructured":"Messing, E. M. et al. Effect of Intravesical Instillation of Gemcitabine vs saline immediately following resection of suspected low-Grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA-J. Am. Med. Assoc. 319(18), 1880\u20131888 (2018).","DOI":"10.1001\/jama.2018.4657"},{"issue":"2","key":"89008_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester, R. J. et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation?. Eur. Urol. 69(2), 231\u2013244 (2016).","journal-title":"Eur. Urol."},{"issue":"1","key":"89008_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/JU.0000000000003015","volume":"209","author":"KK Bree","year":"2023","unstructured":"Bree, K. K. et al. Repeat transurethral resection of muscle-invasive bladder cancer prior to radical cystectomy is prognostic but not therapeutic. J. Urol. 209(1), 140\u2013149 (2023).","journal-title":"J. Urol."},{"issue":"3","key":"89008_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0022-5347(05)66532-9","volume":"165","author":"A Brauers","year":"2001","unstructured":"Brauers, A., Buettner, R. & Jakse, G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?. J. Urol. 165(3), 808\u2013810 (2001).","journal-title":"J. Urol."},{"issue":"5","key":"89008_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi, M. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur. Urol. 41(5), 523\u2013531 (2002).","journal-title":"Eur. Urol."},{"issue":"6 Pt 1","key":"89008_CR20","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","volume":"171","author":"RJ Sylvester","year":"2004","unstructured":"Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J. Urol. 171(6 Pt 1), 2186\u20132190 (2004).","journal-title":"J. Urol."},{"key":"89008_CR21","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han, J., Gu, X., Li, Y. & Wu, Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. 129, 110393 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"89008_CR22","doi-asserted-by":"crossref","unstructured":"Marttila, T. et al. Intravesical Bacillus calmette-guerin versus combination of epirubicin and interferon-alpha2a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study. Eur. Urol. 70\u00a0(2), 341\u2013347 (2016).","DOI":"10.1016\/j.eururo.2016.03.034"},{"issue":"5","key":"89008_CR23","first-page":"CD6885","volume":"11","author":"PF Shang","year":"2011","unstructured":"Shang, P. F. et al. Intravesical bacillus calmette-guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Datab. Syst. Rev. 11(5), CD6885 (2011).","journal-title":"Cochrane Datab. Syst. Rev."},{"key":"89008_CR24","doi-asserted-by":"crossref","unstructured":"Musat, M. G. et al. Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: Systematic literature review (SLR). ClinicoEcon. Outcome Res. 14, 35\u201348 (2022).","DOI":"10.2147\/CEOR.S341896"},{"issue":"6","key":"89008_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","volume":"205","author":"JT Matulay","year":"2021","unstructured":"Matulay, J. T. et al. Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus calmette-guerin: Implications for clinical trial design. J. Urol. 205(6), 1612\u20131621 (2021).","journal-title":"J. Urol."},{"key":"89008_CR26","doi-asserted-by":"crossref","unstructured":"Kamat, A. M. et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations from the international bladder cancer group. J. Clin. Oncol.\u00a034(16), 1935\u20131944 (2016).","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"89008_CR27","doi-asserted-by":"crossref","unstructured":"Grabe-Heyne, K. et al. Intermediate and high-risk non-muscle-invasive bladder cancer: An overview of epidemiology, burden, and unmet needs. Front. Oncol.\u00a013,\u00a01170124 (2023).","DOI":"10.3389\/fonc.2023.1170124"},{"issue":"4","key":"89008_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","volume":"4","author":"WB Tabayoyong","year":"2018","unstructured":"Tabayoyong, W. B. et al. Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer. Eur. Urol. Focus 4(4), 512\u2013521 (2018).","journal-title":"Eur. Urol. Focus"}],"updated-by":[{"DOI":"10.1038\/s41598-025-98177-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89008-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:43:26Z","timestamp":1745415806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89008-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89008"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89008-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-98177-8","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-98177-8","URL":"https:\/\/doi.org\/10.1038\/s41598-025-98177-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval and consent to participate: This retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (XYFY2022-KL340). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"4874"}}